Development History
About Us
2018
2020
2021
2022
2023
2024
2025
2018
Company founded.
2020
Acquired PCFIT™ platform; Completed Series A financing; Recognized as a "Soonicorn" in Hangzhou.
2021
Established the laboratory in Basel, Switzerland; Acquired the APITOPE® technology platform for autoimmune diseases, securing global rights to all products.
2022
Completed Series B financing; WP1301 granted orphan drug designation in Europe and China.
2023
Established Shanghai laboratory; Commenced construction of Zhejiang (Anji) production facility; Completed Series C financing; Acquired Spanish company Diater; WP1302 received FDA approval for Phase II clinical trials in the U.S.
2024
Completed Series D financing; Established Worg Global Commercial Center; Launched German subsidiary.
2025
WP1404, a molecular AIT product, received approval for Phase II clinical trials in Europe; DAP® penicillin allergy diagnostic kit officially approved in Macau SAR.
A wholly-owned subsidiary of Worg PHARMA